Recent Updates
Recently added Catalysts

mometasone furoate

Phase 3

Acute Rhinosinusitis | Small molecule | ENT |Organon & Co.|Last Updated: Aug 15, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials2
Total Enrollment1,962
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00751075Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Phase 3 Study)(Study P02692)PHASE3 COMPLETED 981Dec 1, 2003Jun 22, 2004Aug 15, 2024 -
NCT00750750Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Study P02683)PHASE2 COMPLETED 981Jan 1, 2003Sep 1, 2003Aug 15, 2024 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Average AM/PM major-symptom score (sum of rhinorrhea, post nasal drip, nasal congestion/stuffiness, sinus headache, and facial pain/pressure/tenderness on palpation over the paranasal sinuses) over the Treatment Phase of 15 days.
Over 15 days
Secondary Endpoints
The total-, major-, and individual-symptom scores (for AM, PM, and AM/PM average) by week, and for Days 1-15, and 16-29.
At end of each week, over Days 1-15, and Days 16-29
Time to onset of action in the major-symptom score, defined as the first day active treatment was statistically significantly different from placebo, and sustained thereafter.
Throughout the Treatment Period
Comparison between the groups of therapeutic response
At Visit 4 or the last treatment visit
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1ACTIVE_COMPARATORMFNS once daily
2EXPERIMENTALMFNS twice daily
3ACTIVE_COMPARATORAmoxicillin
4PLACEBO_COMPARATORPlacebo
Interventions
NameTypeDescription
mometasone furoate nasal spray (MFNS)DRUGPlacebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
MFNSDRUGPlacebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
AmoxicillinDRUGAmoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
PlaceboDRUGPlacebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
Unlock Study Design Details
Eligibility Criteria
Age Range12 Years — N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: Subjects must: * have been diagnosed with acute rhinosinusitis * have had signs and symptoms of rhinosinusitis for at least 7 but not more than 28 days prior to Baseline * have had a major symptom score \>=5 and \<=12 at the Screening and Baseline, and no more than 3 of the 5 m...

Unlock Eligibility Criteria